Drugs - Xagena.net - Update in Medicine

Search results for "Xofigo"

EU: Xofigo for adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases, approved

Bayer HealthCare has announced that the European Commission ( EC ) has granted marketing authorisation for Xofigo 1000 kBq/ml, solution for injection ( Radium Ra 223 dichloride ) for the treatment of ... read article

Radium-223 has reduced the risk of death by 30.5% in castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease

Bayer HealthCare has announced that the New England Journal of Medicine ( NEJM ) has published results from Phase III ALSYMPCA study of Radium 223 dichloride ( Alpharadin; 223-Ra; Radium-223 ). In su ... read article

Castration-resistant prostate cancer: significant overall survival benefit observed with Radium 223

Bayer HealthCare has announced that data from the pivotal Phase III ALSYMPCA ( ALpharadin in SYMptomatic Prostate CAncer ) trial of its drug Radium 223 dichloride ( Radium 223 ) in castration-resistan ... read article

Xofigo for advanced prostate cancer, FDA approved

The FDA ( Food and Drug Administration ) has approved Xofigo ( Radium Ra 223 dichloride ) to treat men with symptomatic late-stage castration-resistant prostate cancer that has spread to bones but not ... read article

Focus

New indication for Eylea in EU: treatment of visual impairment due to macular edema secondary to central retinal vein occlusion

Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ... read article

Ibrutinib shows efficacy as treatment for chronic lymphocytic leukemia and mantle cell lymphoma

Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ... read article

Olmesartan Medoxomil can cause sprue-like enteropathy

FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics ) can cause intestinal problems know ... read article

Barrett's esophagus: Acetylsalicylic acid may fight cancer by slowing DNA damage

Aspirin ( Acetylsalicylic acid ) is known to lower risk for some cancers, and a new study led by a UC San Francisco researcher, Carlo Maley, points to a possible explanation, with the discovery that A ... read article

Metastatic or unresectable melanoma: FDA approves Tafinlar and Mekinist

The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), for patients with advanced ( metastatic ) or unresectable melanoma, the most d ... read article

Giant cell tumor of the bone: FDA approves Xgeva

The Food and Drug Administration ( FDA ) has expanded the use of Xgeva ( Denosumab ) to treat adults and some adolescents with giant cell tumor of the bone ( GCTB ), a rare and usually non-cancerous t ... read article

Riociguat has demonstrated significant and sustained improvements in 6MWD and WHO functional class in patients with pulmonary arterial hypertension

Data from the interim analysis of the on-going PATENT-2 trial with Riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Thoracic Societ ... read article

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

Janssen Pharmaceuticals has announced the FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new ... read article